Homepage Top Section2

Co-led by global investors Insight Partners and M Ventures, the financing round has also seen participation from Gaingels and One Way Ventures. ImmuneBridge is developing allogeneic NK cell-based

The receipt of the drug distribution licence by Hainan Asieris is an important step towards improving drug circulation services, standardising management, and promoting drug imports and distribution in

Located at the TÜBITAK MAM Gebze campus in Kocaeli province close to Istanbul, the MEDIBIYO facility can generate biotechnological drugs and vaccines that align with good manufacturing practice

With regard to the closure of the deal, AcelRx got a total of around $2.7m from Aguettant and Alora. Alora agreed to acquire all assets associated to DSUVIA

Entresto (sacubitril/valsartan) is intended for treating symptomatic chronic heart failure with left ventricular systolic dysfunction in patients who are aged from 1 to <18 years. Novartis global head

A tumour infiltrating lymphocyte (TIL) therapy,  lifileucel is designed to treat patients with advanced (unresectable or metastatic) melanoma who advanced  on or after prior anti-PD-1/L1 therapy and targeted therapy.

Under the deal terms, Macomics will be responsible for identifying and characterising the antibody candidates against a new target leveraging its Enigmac macrophage drug discovery platform. Ono Pharmaceutical

PBP1510 will mainly act on a tumour-specific protein called pancreatic adenocarcinoma upregulated factor (PAUF), which is overexpressed in most pancreatic cancer patients. PAUF overexpression is said to advance

Earlier, ARO-APOC3 received Orphan Drug designation from the FDA and the European Union. ARO-APOC3 is the firm’s investigational RNAi therapeutic targeting apolipoprotein C-III (APOC3). It is being developed